Management of peyronies disease and erectile dysfunction
Reading File
Finding Sources
Finding Sources
Searching PubMed
"Peyronie disease" AND treatment
Searching PubMed
"erectile dysfunction" AND management
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Searching the Web
Peyronie's disease erectile dysfunction management guidelines 2024 2025 AUA EAU
I now have all the information needed for a comprehensive response. Let me compile this.
Management of Peyronie's Disease and Erectile Dysfunction
PEYRONIE'S DISEASE (PD)
Overview
Peyronie's disease is an acquired, progressive connective-tissue disorder of the tunica albuginea characterized by fibrous plaque formation. Key features include penile pain, palpable plaque, penile curvature/deformity, and difficulty with penetrative intercourse. Prevalence is 3–9% of men (often underreported), peak age 45–60 years. ED coexists in 20–58% of PD patients — making the two conditions deeply intertwined clinically.
Pathogenesis
The disease results from repetitive microtrauma to the erect or semi-erect penis → delamination of the tunica albuginea layers → microhemorrhage → aberrant wound healing cascade → fibrous plaque. Genetic predisposition, autoimmune factors, and TGF-β1–mediated inflammation are also implicated.
Disease Phases
| Phase | Characteristics | Duration |
|---|---|---|
| Acute (inflammatory) | Penile pain (35–45%), active plaque growth, progressive deformity | First 6–12 months |
| Chronic (stable) | Pain resolves (~90% by 6 months), plaque/curvature stabilize | After 6–12 months |
Without treatment: worsens in 30–50%, stabilizes in 47–67%, improves spontaneously in only 3–13%.
Diagnosis
- History: sexual history, onset, pain, curvature direction, penetrative difficulty, psychosocial impact
- Examination: palpable tunical plaque; check hands/feet for Dupuytren's contracture (co-occurs in ~21%) or Ledderhose disease
- Objective assessment: stretched penile length, plaque size; erect photography (natural, VED-assisted, or post-ICI)
- Imaging: Doppler duplex ultrasound — highest sensitivity for calcified and soft-tissue plaques; assesses arterial/venous status simultaneously
Treatment of PD: A Phase-Based Approach
1. Conservative / Observation
In the acute phase, conservative management is appropriate if the deformity is mild and non-bothersome. Psychosexual counseling should be offered to all patients given the high prevalence of depression, anxiety, and relationship distress (reported by 77–94%).
2. Medical (Non-surgical) Treatment — Acute/Active Phase
Goal: alleviate pain, halt progression, stabilize plaque and deformity.
Oral Therapies
| Agent | Mechanism | Evidence |
|---|---|---|
| Pentoxifylline (first-line oral) | Nonspecific PDE inhibitor; inhibits TGF-β1, reduces collagen type I, increases NO | Preferred for multimodal therapy; used with ILI and traction |
| Vitamin E | Antioxidant | Widely used historically; randomized trials show minimal benefit |
| Colchicine | Anti-inflammatory, anti-fibrotic | Limited RCT evidence |
| Tamoxifen | Anti-TGF-β | Not recommended in current guidelines |
| PDE5 inhibitors | Increase NO/cGMP, anti-fibrotic | May help co-existing ED; used adjunctively |
| Carnitine, CoQ10, omega-3 | Antioxidant/anti-inflammatory | Preliminary data; RCTs disappointing |
Most oral agents have failed to demonstrate significant benefit in well-designed RCTs. Pentoxifylline within a multimodal strategy remains the recommended oral component.
Intralesional Injection (ILI) Therapy — First-Line Interventional
Three agents with RCT efficacy data:
| Agent | Notes |
|---|---|
| Collagenase Clostridium Histolyticum (CCH / Xiaflex) | Only FDA-approved ILI for PD. Indicated for stable disease, curvature 30°–90°, intact erectile function. Each treatment cycle = 2 injections 24–72 hrs apart; cycles ≥6 weeks apart. Penile modeling mandatory 48 hrs post-2nd injection. REMS program required. AEs: bruising, swelling, penile rupture (rare, ~1%) |
| Verapamil | Calcium channel blocker; inhibits fibroblast proliferation; safe and inexpensive; used off-label |
| Interferon-α-2b | Reduces fibroblast proliferation; efficacy shown in RCTs; less widely available |
Physical/Device-Based Therapies (Adjunct)
- Penile traction therapy (PTT): Used alongside ILI; helps maintain/restore penile length, may reduce curvature — especially in the acute phase
- Vacuum erection device (VED): Adjunct to help preserve length and aid in monitoring curvature
- Extracorporeal shockwave therapy (ESWT): May reduce pain but does NOT reduce curvature — not recommended for deformity correction
- Topical therapies / iontophoresis / radiation therapy: Not currently recommended by AUA or EAU guidelines
3. Surgical Treatment — Stable/Chronic Phase Only
Indications (after ≥3–12 months of disease stability, failed conservative therapy):
- Deformity impairing sexual function
- Stable disease
- Extensive plaque calcification
- Failed minimally invasive treatment
- Desire for rapid, reliable correction
Surgical categories:
| Category | Procedures | Best For |
|---|---|---|
| Penile shortening (plication) | Nesbit procedure, modified Nesbit, tunical plication | Adequate penile length, curvature <60°–70°, good erectile function |
| Penile lengthening (grafting) | Plaque incision/excision + graft (pericardium, dermis, SIS, synthetic) | Complex deformities (hourglass, hinge), severe curvature, preserving length |
| Penile prosthesis implantation | Inflatable penile prosthesis (IPP) with or without modeling/plication | PD with ED refractory to medical therapy — this is the surgical treatment of choice in this group |
Surgical risks: de novo or worsened ED, penile shortening, hypoesthesia, recurrent curvature, chronic pain.
When PD coexists with significant ED unresponsive to medications, penile prosthesis implantation is the preferred surgical option, as it addresses both conditions simultaneously. Intraoperative modeling can correct residual curvature at the time of IPP placement.
ERECTILE DYSFUNCTION (ED)
Definition & Epidemiology
ED is defined as the consistent or recurrent inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance (NIH 1993 / AUA 2018). Affects ~30 million men in the US; prevalence increases with age.
Pathophysiology
Erection depends on parasympathetic-mediated release of nitric oxide (NO) from non-adrenergic, non-cholinergic (NANC) nerves → activates soluble guanylate cyclase → ↑ cGMP → PKG activation → smooth muscle relaxation in cavernosal arterioles and trabeculae → arterial inflow → venous compression against tunica albuginea → rigidity. PDE5 degrades cGMP, terminating the erection.
Causes are multifactorial:
- Vascular (most common): atherosclerosis, hypertension, diabetes, hyperlipidemia
- Neurogenic: spinal cord injury, radical prostatectomy, pelvic radiation, diabetes, MS
- Hormonal: hypogonadism, hyperprolactinemia, thyroid disease
- Psychogenic: performance anxiety, depression, relationship dysfunction
- Drug-induced: antihypertensives (especially thiazides, non-selective β-blockers), antidepressants (SSRIs), antipsychotics, antiandrogens (~25% of ED cases are medication-related)
ED may precede symptomatic cardiovascular disease — men presenting with ED should receive a cardiac risk assessment (Princeton Consensus guidelines).
Management of ED
Step 1 — Initial Evaluation
- SHIM (Sexual Health Inventory for Men) or IIEF questionnaire
- Full history: risk factors, medications, psychosocial, libido, partner relationship
- Examination: genitalia, secondary sexual characteristics, vascular, neurological
- Labs: FPG/HbA1c, lipids, renal function, urinalysis, total testosterone (morning). Add free T, LH, prolactin if signs of hypogonadism or low total T.
Step 2 — Address Reversible Causes
- Lifestyle modification: weight loss (improves erectile function in obese men), exercise, smoking cessation, alcohol reduction
- Medication review: substitute offending drugs where possible (e.g., switch from non-selective β-blocker to nebivolol; switch from SSRI to bupropion for antidepressant-induced ED)
- Treat underlying conditions: optimize glycemic control, treat hypogonadism (testosterone replacement restores libido and often improves erectile response)
Step 3 — Pharmacological Treatment
First-Line: PDE5 Inhibitors
The advent of oral PDE5 inhibitors has made them the drugs of first choice for most ED patients.
| Drug | Onset | Duration | Key Notes |
|---|---|---|---|
| Sildenafil (Viagra) | ~30–60 min | ~4–6 h | Take on empty stomach; affected by fatty meals |
| Tadalafil (Cialis) | ~30 min | ~36 h ("weekend pill"); also daily dosing (5 mg/day) | Food-independent; also treats BPH |
| Vardenafil (Levitra) | ~30–60 min | ~4–6 h | Slightly higher PDE5 selectivity vs. sildenafil |
| Avanafil (Stendra) | ~15 min | ~6 h | Fastest onset; higher PDE5 selectivity |
All are metabolized by CYP3A4 (minor CYP2C9 for sildenafil). Excreted predominantly via feces.
Adverse effects: headache, flushing, nasal congestion, dyspepsia, dizziness; sildenafil/vardenafil → blue-green visual disturbance (PDE6 inhibition in retina); tadalafil → back/myalgia.
Contraindications/Precautions:
- Absolute CI: concurrent nitrate use (risk of severe hypotension; minimum 6-hour interval required between a nitrate dose and a PDE5i; for tadalafil some sources suggest 24–48 hours given its longer half-life)
- Caution with α-blockers (orthostatic hypotension); use lowest dose; avoid in recent stroke/MI
- PDE5is are ineffective in men with complete loss of nerve supply (e.g., bilateral cavernous nerve injury after RP) or absent libido — they require intact NO pathway
Special populations:
- Diabetes/ED: PDE5is are effective but may require higher doses; success rate ~50–70%
- Post-radical prostatectomy: early penile rehabilitation with PDE5is (daily or on-demand) may improve recovery; ICI is often needed
- Antidepressant-induced ED: add PDE5i, switch to bupropion, or consider drug holiday
- Spinal cord injury: PDE5is can be effective with preserved reflex erections
Second-Line: Intracavernosal/Intraurethral Therapy
Used when PDE5is fail or are contraindicated.
| Route | Agent | Notes |
|---|---|---|
| Intracavernosal injection (ICI) | Alprostadil (PGE1) (most effective), papaverine, phentolamine; bi- or tri-mix combinations | Effective in 70–90% of men who fail oral therapy; priapism risk |
| Intraurethral (MUSE) | Alprostadil suppository | Less effective than ICI (~30–65%); urethral burning, partner vaginal irritation |
| ICI — phentolamine | α-adrenergic blocker | Used in combination; not as monotherapy |
Mechanical Devices
- Vacuum Erection Device (VED): Negative pressure draws blood into corpora; tension ring maintains erection. Effective, non-invasive; often useful in post-prostatectomy rehabilitation. Main drawback: "cold, pivot-point" erection; less spontaneous.
Third-Line: Surgical — Penile Prosthesis Implantation
Indicated when medical and conservative therapies fail, or in certain conditions (e.g., PD + ED, severe Peyronie's, post-priapism fibrosis).
- Inflatable Penile Prosthesis (IPP): 2-piece or 3-piece; gold standard for refractory ED; high satisfaction rates (>90% patient and partner)
- Semi-rigid (malleable) prosthesis: simpler, fewer mechanical failures; less "natural" appearance
Special Consideration: PD + ED — Integrated Management
When both conditions coexist (occurring in up to 58% of PD patients), management should be coordinated:
- Assess which is the primary complaint — curvature vs. erectile rigidity
- If mild–moderate ED + active PD: pentoxifylline + PDE5i + ILI (CCH or verapamil) ± traction
- If moderate–severe ED + stable PD: penile prosthesis implantation is the preferred surgical option — IPP corrects rigidity; residual curvature is managed intraoperatively via manual modeling or adjunct plication
- Psychosexual counseling at all stages — PD+ED combined carries significant psychological burden
Summary Algorithm
ED Diagnosis
│
├─ Lifestyle modification + treat reversible causes (all patients)
│
├─ 1st Line: PDE5 inhibitor (all neurologically/hormonally intact patients)
│ └─ Testosterone deficiency? → Testosterone replacement FIRST
│
├─ 2nd Line: VED, ICI (alprostadil ± papaverine ± phentolamine), MUSE
│
└─ 3rd Line: Penile prosthesis implantation
PD Diagnosis
│
├─ Acute phase: Pentoxifylline + ILI (CCH/verapamil) + traction ± PDE5i
│
├─ Stable phase + adequate erectile function: ILI (CCH) ± plication surgery
│
└─ Stable phase + significant ED: Penile prosthesis implantation ± intraoperative modeling
Sources:
- Smith and Tanagho's General Urology, 19th Ed. — Peyronie's Disease, pp. 638–639
- Campbell-Walsh-Wein Urology — Etiology, ED in PD, Psychological Aspects, pp. 2130–2134
- Goodman & Gilman's Pharmacological Basis of Therapeutics — PDE5 Inhibitors, p. 1018
- Katzung's Basic and Clinical Pharmacology, 16th Ed. — Drugs for ED, p. 309
- Textbook of Family Medicine, 9th Ed. — Erectile Dysfunction, p. 1193–1194
- AUA Peyronie's Disease Guideline — CCH for stable PD with curvature 30°–90°
- AUA Erectile Dysfunction Guideline (2018)
- ICSM 2024 PD Recommendations (PMID: 41359447) — most recent international consensus
This is a shared conversation. Sign in to Orris to start your own chat.